Vertex Pharma (VRTX) Announces FDA Approval of KALYDECO as First CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age
April 30, 2019 8:31 AM
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) for use in ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
